| Chemical Name |
Atrasentan (hydrochloride) |
| CAS Number |
195733-43-8 |
| MDL Number |
MFCD13194884 |
| Molecular Formula |
C29H39ClN2O6 |
| Molecular Weight |
547.08 |
| Synonyms |
ABT-627 (hydrochloride);(+)-A 127722 (hydrochloride);A-147627 (hydrochloride) |
Introduction of 195733-43-8 :
Atrasentan hydrochloride (ABT-627 hydrochloride) is a selective endothelin A receptor antagonist with an IC50 of 0.0551 nM for ETA[1]. IC50 & Target: IC50: 0.055 nM (ETA) In Vitro: Atrasentan hydrochloride (ABT-627 hydrochloride) (0-50 μM) significantly inhibits LNCaP and C4-2b prostate cancer cell growth[2]. Atrasentan profoundly induces several CYPs and drug transporters (e.g. 12-fold induction of CYP3A4 at 50 μM). It is a moderate P-gp inhibitor (IC50 in P388/dx cells=15.1±1.6 μM) and a weak BCRP inhibitor (IC50 in MDCKII-BCRP cells=59.8±11 μM)[3]. In Vivo: Atrasentan hydrochloride (ABT-627 hydrochloride) (3 mg/kg, p.o.) inhibits the pressor response induced by big endothelin-1 (1 nmol/kg) in pithed rats[1]. Aatrasentan (ABT-627, 10 mg/kg, i.p.) inhibits the C4-2b tumor growth within the bone environment to some extent in the SCID-hu model[2].
| Purity |
NLT 98% |
| Storage |
at 20ºC 2 years |
*The above information is for reference only.
